Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Apollo Endosurgery, Inc.APEN · Entity 114713 | Director | February 28, 2018 | March 02, 2018 |
| Conformis IncCFMS · Entity 109987 | Director | June 04, 2021 | June 08, 2021 |
| HAEMONETICS CORPHAE · Entity 3953 | Director | February 04, 2021 | February 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Apollo Endosurgery, Inc.
Report date February 28, 2018 · Filed March 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,367 |
Reported balance
After 2018-02-28 transaction · row 1
1 source rowRow 1 · 2018-02-28 · Grant · Acquired 6,269 · Balance 11,367 F1: Fully vested at one year anniversary of grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.58 · Expires 2028-02-28 | Direct | 21,488 |
Reported balance
After 2018-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-28 · Grant · Acquired 21,488 · Balance 21,488 F1: Fully vested at one year anniversary of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested at one year anniversary of grant date.
Conformis Inc
Report date June 04, 2021 · Filed June 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 122,223 |
Reported balance
After 2021-06-04 transaction · row 1
1 source rowRow 1 · 2021-06-04 · Grant · Acquired 122,223 · Balance 122,223 |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 253,568 |
Reported balance
Holding disclosure · report date 2021-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 253,568 F1: The shares are held directly by The Richard J. Meelia 1997 Revocable Trust udt dated 12/29/1997 (the "Trust"). The Reporting Person's immediate family members are beneficiaries of the Trust. The reporting person disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest, if any, and this report should not be deemed an admission that the reporting person is the beneficial owner of the Trust's shares for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held directly by The Richard J. Meelia 1997 Revocable Trust udt dated 12/29/1997 (the "Trust"). The Reporting Person's immediate family members are beneficiaries of the Trust. The reporting person disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest, if any, and this report should not be deemed an admission that the reporting person is the beneficial owner of the Trust's shares for purposes of Section 16 or for any other purposes.
HAEMONETICS CORP
Report date February 04, 2021 · Filed February 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,050 |
Last balance in matching sequence
After 2021-02-04 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-02-04 · Exercise / conversion · Acquired 10,353 · Balance 42,403 F1: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4. F2: This number includes unvested restricted stock units previously reported. Row 2 · 2021-02-04 · Sale · Disposed 10,353 · Balance 32,050 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.39 to $135.30, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: This number includes unvested restricted stock units previously reported. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.50 · Expires 2021-07-23 | Direct | 0 |
Reported balance
After 2021-02-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-04 · Exercise / conversion · Disposed 10,353 · Balance 0 F1: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4. F4: Options vest 100% on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4.
F2: This number includes unvested restricted stock units previously reported.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.39 to $135.30, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: Options vest 100% on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2021 Filed Jun 8, 2021 17:53 UTC | Conformis Inc CFMS · Entity 109987 | GrantCommon Stock | 122,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001305773-21-000078 · wf-form4_162318915722358.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,223 Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:51 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 10,353 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001127602-21-004202 · form4.xml · derivative · entry 3 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,353 shares Expires 2021-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4. F4 · derivative.exercise_date: Options vest 100% on the first anniversary of the date of grant. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:51 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 10,353 | $134.64 | $1,393,927.92 |
DisclosureSEC source: 0001127602-21-004202 · form4.xml · nonDerivative · entry 2 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,050 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.39 to $135.30, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:51 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 10,353 | $35.50 | $367,557.38 |
DisclosureSEC source: 0001127602-21-004202 · form4.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 21:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,983 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-021988 · form4.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,050 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 14, 2020 Filed May 18, 2020 18:33 UTC | Conformis Inc CFMS · Entity 109987 | GrantCommon Stock | 111,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001305773-20-000070 · wf-form4_158984116268193.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,467 Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 22:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 6,573 | $0.00 Strike: $45.45 | $0.00 |
DisclosureSEC source: 0001127602-19-032637 · form4.xml · derivative · entry 3 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,573 shares Expires 2020-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 22:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 6,573 | $118.15 | $776,599.95 |
DisclosureSEC source: 0001127602-19-032637 · form4.xml · nonDerivative · entry 2 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,067 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.00 to $118.64, inclusive. the reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 22:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 6,573 | $45.45 | $298,742.85 |
DisclosureSEC source: 0001127602-19-032637 · form4.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 21:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-025270 · form4.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,067 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| May 06, 2019 Filed May 8, 2019 18:44 UTC | Conformis Inc CFMS · Entity 109987 | GrantCommon Stock | 48,532 | $0.00 | $0.00 |
DisclosureSEC source: 0001305773-19-000065 · wf-form4_155735543482506.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,213 Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:04 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,196 | $0.00 Strike: $36.37 | $0.00 |
DisclosureSEC source: 0001127602-18-036615 · form4.xml · derivative · entry 3 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,196 shares Expires 2019-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:04 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 8,196 | $102.86 | $843,040.56 |
DisclosureSEC source: 0001127602-18-036615 · form4.xml · nonDerivative · entry 2 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,607 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.56 to $103.26, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:04 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 8,196 | $36.37 | $298,088.52 |
DisclosureSEC source: 0001127602-18-036615 · form4.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 21:55 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024049 · form4.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,607 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| May 07, 2018 Filed May 9, 2018 17:36 UTC | Conformis Inc CFMS · Entity 109987 | GrantCommon Stock | 45,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001305773-18-000054 · wf-form4_152590180343507.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,681 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 14:43 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | GrantStock Option (Right to Buy) · Derivative | 21,488 | $6.58 Strike: $6.58 | $141,391.04 |
DisclosureSEC source: 0001251769-18-000017 · wf-form4_152001978992777.xml · derivative · entry 2 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,488 Underlying: Common Stock · 21,488 shares Expires 2028-02-28 F1 · date: Fully vested at one year anniversary of grant date. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 14:43 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | GrantCommon Stock | 6,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001251769-18-000017 · wf-form4_152001978992777.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,367 F1 · date: Fully vested at one year anniversary of grant date. Read SEC document |
| August 10, 2017 Filed Aug 15, 2017 23:06 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 7,118 | $0.00 Strike: $34.41 | $0.00 |
DisclosureSEC source: 0001127602-17-025677 · form4.xml · derivative · entry 6 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,118 shares Expires 2018-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2017 Filed Aug 15, 2017 23:06 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 16,968 | $0.00 Strike: $32.96 | $0.00 |
DisclosureSEC source: 0001127602-17-025677 · form4.xml · derivative · entry 5 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,968 shares Expires 2018-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2017 Filed Aug 15, 2017 23:06 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 7,118 | $42.10 | $299,700.54 |
DisclosureSEC source: 0001127602-17-025677 · form4.xml · nonDerivative · entry 4 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,911 Read SEC document |
| August 10, 2017 Filed Aug 15, 2017 23:06 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 7,118 | $34.41 | $244,894.79 |
DisclosureSEC source: 0001127602-17-025677 · form4.xml · nonDerivative · entry 3 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents the exercise and sale of stock options which expire in July 2018. Read SEC document |
| August 10, 2017 Filed Aug 15, 2017 23:06 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 16,968 | $42.02 | $712,995.36 |
DisclosureSEC source: 0001127602-17-025677 · form4.xml · nonDerivative · entry 2 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,911 Read SEC document |
| August 10, 2017 Filed Aug 15, 2017 23:06 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 16,968 | $32.96 | $559,265.28 |
DisclosureSEC source: 0001127602-17-025677 · form4.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the exercise and sale of stock options which expire in June 2018. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 21:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 4,329 | $39.27 | $169,999.83 |
DisclosureSEC source: 0001127602-17-024390 · form4.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,911 F1 · shares: Restricted Stock Unit grant which vest 100% on the first anniversary of the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 18:20 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | PurchaseCommon Stock | 45,454 | $5.50 | $249,997.00 |
DisclosureSEC source: 0001179110-17-010719 · edgar.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Richard J. Meelia 1997 Revocable Trust Disclosed balance after: 45,454 F1 · ownership.nature: The Reporting Person is the trustee of The Richard Meelia 1997 Revocable Trust. Read SEC document |
| May 25, 2017 Filed May 30, 2017 17:56 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 9,468 | $6.50 Strike: $6.50 | $61,542.00 |
DisclosureSEC source: 0001251769-17-000042 · edgardoc.xml · derivative · entry 5 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,468 Underlying: Common Stock · 9,468 shares Expires 2027-05-25 F1 · date: Fully vested at one year anniversary of grant date. Read SEC document |
| May 25, 2017 Filed May 30, 2017 17:56 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | GrantCommon Stock | 5,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001251769-17-000042 · edgardoc.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,098 F1 · date: Fully vested at one year anniversary of grant date. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:13 UTC | Conformis Inc CFMS · Entity 109987 | GrantCommon Stock | 21,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001305773-17-000088 · wf-form4_149507000600102.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,921 Read SEC document |
| December 29, 2016 Filed Dec 30, 2016 08:32 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | OtherStock Options · Derivative | 5,751 | Not disclosed Strike: $3.36 | Not disclosed |
DisclosureSEC source: 0001179110-16-033601 · edgar.xml · derivative · entry 3 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,751 Underlying: Common Stock · 5,751 shares Expires 2024-07-07 F1 · kind: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). PPursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding. F4 · price: On July 8, 2014, Reporting Person was granted an option to purchase 100,000 shares of the common stock of Old Apollo under Old Apollo's Equity Incentive Plan at an exercise price of $0.19 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 5,751 shares of the Issuer's common stock at a per share exercise price of $3.36. Subject to Reporting Person's continued service to the Issuer 1/48th of the option will vest and become exercisable on each of the 48 months commencing on September 1, 2013. 100% of any unvested portion of the option will become fully vested and exercisable if, after the occurrence of a liquidation event, as defined in the Issuer's amended and restated certificate of incorporation. F4 · derivative.exercise_date: On July 8, 2014, Reporting Person was granted an option to purchase 100,000 shares of the common stock of Old Apollo under Old Apollo's Equity Incentive Plan at an exercise price of $0.19 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 5,751 shares of the Issuer's common stock at a per share exercise price of $3.36. Subject to Reporting Person's continued service to the Issuer 1/48th of the option will vest and become exercisable on each of the 48 months commencing on September 1, 2013. 100% of any unvested portion of the option will become fully vested and exercisable if, after the occurrence of a liquidation event, as defined in the Issuer's amended and restated certificate of incorporation. Read SEC document |
| December 29, 2016 Filed Dec 30, 2016 08:32 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | OtherStock Options · Derivative | 9,202 | Not disclosed Strike: $2.09 | Not disclosed |
DisclosureSEC source: 0001179110-16-033601 · edgar.xml · derivative · entry 2 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,202 Underlying: Common Stock · 9,202 shares Expires 2022-07-29 F1 · kind: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). PPursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding. F3 · price: On July 30, 2012, Reporting Person was granted an option to purchase 160,000 shares of the common stock of Old Apollo under Old Apollo's Equity Incentive Plan at an exercise price of $0.12 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 9,202 shares of the Issuer's common stock at a per share exercise price of $2.09. This option has fully vested. F3 · derivative.exercise_date: On July 30, 2012, Reporting Person was granted an option to purchase 160,000 shares of the common stock of Old Apollo under Old Apollo's Equity Incentive Plan at an exercise price of $0.12 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 9,202 shares of the Issuer's common stock at a per share exercise price of $2.09. This option has fully vested. Read SEC document |
| December 29, 2016 Filed Dec 30, 2016 08:32 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | OtherCommon Stock | 17,501 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-033601 · edgar.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Meelia Ventures, LLC Disclosed balance after: 17,501 F1 · kind: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). PPursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding. F1 · price: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). PPursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding. F2 · ownership.nature: These securities are held in the name of Meelia Ventures, LLC. The Reporting Person has a controlling interest in Meelia Ventures, LLC and may be deemed to be the beneficial owner of the securities held by Meelia Ventures, LLC. Read SEC document |
| December 29, 2016 Filed May 30, 2017 17:56 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | OtherCommon Stock | 17,501 | $1.36 | $23,801.36 |
DisclosureSEC source: 0001251769-17-000042 · edgardoc.xml · nonDerivative · entry 2 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Corporation Disclosed balance after: 17,501 Read SEC document |
| July 08, 2014 Filed May 30, 2017 17:56 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 5,751 | $3.36 Strike: $3.36 | $19,323.36 |
DisclosureSEC source: 0001251769-17-000042 · edgardoc.xml · derivative · entry 4 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,751 Underlying: Common Stock · 5,751 shares Expires 2024-07-08 Read SEC document |
| July 30, 2012 Filed May 30, 2017 17:56 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 9,202 | $2.09 Strike: $2.09 | $19,232.18 |
DisclosureSEC source: 0001251769-17-000042 · edgardoc.xml · derivative · entry 3 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,202 Underlying: Common Stock · 9,202 shares Expires 2022-07-30 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.